Obstructive Sleep Apnea trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Obstructive Sleep Apnea. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month8 studies across 3 companies, in the next 180 days.
September 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| NYXH.BR | Nyxoah S.A. | Safety and Effectiveness of the Genio® bilAteral Stimulation for Treatment of Complete Concentric CollapsE and OSA.NCT05592002Primary Effectiveness Endpoint | Not applicable | Active, not recruiting | Sep 2026 | ≤ 41 d | 2025-09-05 |
October 2026 3
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| NYXH.BR | Nyxoah S.A. | A Post-market Clinical Follow up of the Genio® System for the Treatment of Obstructive Sleep Apnea in AdultsNCT04031040Incidence of device-related Serious Adverse Events (SADEs) | Not applicable | Active, not recruiting | 2026-10-30 | in 71 d | 2026-03-04 |
| RMD | ResMed | Registry Study on Prescription, Patient Pathways, Therapy Efficacy and Usage of Mandibular Advancement Devices in Obstructive Sleep Apnea - PATT-OSA RegistryNCT03924817observationalChanges of the Apnoea-Hypopnea-Index (AHI) at baseline compared to a follow-up after 3 months | — | Active, not recruiting | 2026-10-31 | in 72 d | 2026-08-13 |
| RMD | ResMed | Exploration of Current and New Technologies for Accuracy of Diagnosing OSANCT07485582observationalSensitivity | — | Not yet recruiting | Oct 2026 | ≤ 72 d | 2026-08-19 |
November 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| LLY | Eli Lilly and Company | A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or OverweightNCT06649045Change from Baseline in Apnea-Hypopnea Index (AHI) | Phase 3 | Active, not recruiting | Nov 2026 | ≤ 102 d | 2025-09-29 |
December 2026 3
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| RMD | ResMed | Study of Min-Max APAP Recommender ToolNCT07400861Mean residual AHI | Not applicable | Not yet recruiting | 2026-12-01 | in 103 d | 2026-02-12 |
| RMD | ResMed | INFORMing Patients With Oximetry Data to Improve MAD EngagementNCT07564310Mean overall patient reported experience measure (PREM) questionnaire score | Phase 4 | Not yet recruiting | 2026-12-01 | in 103 d | 2026-05-04 |
| RMD | ResMed | Data Collection Study to Review Novel Methods for Diagnosing Obstructive Sleep ApneaNCT06930404observationalCorrelation of measurement and obstructive sleep apnea status | — | Recruiting | 2026-12-30 | in 132 d | 2026-05-19 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Obstructive Sleep Apnea
most recently updated first111 studies match. Showing the first 100 of 111 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RMD | ResMed | $31.7B | Exploration of Current and New Technologies for Accuracy of Diagnosing OSANCT07485582observationalSensitivity | — | Not yet recruiting | Device: Device A, Device B, Device C, Device D, Device E · Diagnostic test: Screener A | Obstructive Sleep Apnea | 90 | Sep 2026 | Oct 2026 | ≤ 72 d | 2026-08-19 |
| RMD | ResMed | $31.7B | Long-term Observation of PAP-therapy With Telemonitoring: Telemedicine Registry TelePAPNCT03043716observationalUsage Patterns of PAP therapy with telemonitoring, assessed by data continuously recorded by the device and transferred via telemonitoring | — | Completed | Other: PAP therapy with telemonitoring | Obstructive Sleep Apnea, Central Sleep Apnea, Mixed Sleep Apnea | 14,147 | 2017-08-01 | 2026-07-31actual | — | 2026-08-17 |
| AMGN | Amgen | $229.9B | Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) TherapyNCT07226765Change in Apnea-hypopnea Index (AHI) from baseline at Week 52 | Phase 3 | Recruiting | Drug: Maridebart cafraglutide, Placebo | Obstructive Sleep Apnea | 250 | 2025-11-25 | 2027-09-29 | in 405 d | 2026-08-14 |
| RMD | ResMed | $31.7B | Registry Study on Prescription, Patient Pathways, Therapy Efficacy and Usage of Mandibular Advancement Devices in Obstructive Sleep Apnea - PATT-OSA RegistryNCT03924817observationalChanges of the Apnoea-Hypopnea-Index (AHI) at baseline compared to a follow-up after 3 months | — | Active, not recruiting | — | Obstructive Sleep Apnea | 500 | 2024-02-01 | 2026-10-31 | in 72 d | 2026-08-13 |
| IXHL | Incannex Healthcare Ltd | $116M | DReAMzz- Dronabinol and Acetazolamide Medication for Sleep Apnea (ZZ). Dose Confirmation Crossover Study for IHL-42X in Subjects With Obstructive Sleep Apnea.NCT07635563Change in AHI4 at the end of each treatment period compared to baseline | Phase 2 | Recruiting | Drug: IHL-42X: 2.5 mg dronabinol + 125 mg acetazolamide, IHL-42X: 5 mg dronabinol + 125 mg acetazolamide, IHL-42X: 7.5 mg dronabinol + 125 mg acetazolamide, IHL-42X: 2.5 mg dronabinol + 250 mg acetazolamide, IHL-42X: 5 mg dronabinol + 250 mg acetazolamide, IHL-42X: 7.5 mg dronabinol + 250 mg acetazolamide, IHL-42X: 2.5 mg dronabinol + 375 mg acetazolamide, IHL-42X: 5 mg dronabinol + 375 mg acetazolamide, IHL-42X: 7.5 mg dronabinol + 375 mg acetazolamide, Placebo: Negative control | Obstructive Sleep Apnea (OSA) | 120 | 2026-07-21 | Apr 2027 | ≤ 253 d | 2026-08-13 |
| APMD | Apnimed | — | Parallel Arm Trial of AD109 and AD504 In Patients With OSANCT05071612results2026-08-12Change in Apnea-Hypopnea Index (AHI4) From Baseline: Combined AD109 Arms vs. Placebo | Phase 2 | Completed | Drug: AD109, AD504, Atomoxetine Hydrochloride, Placebo | OSA - Obstructive Sleep Apnea | 294 | 2021-11-29 | 2022-07-20actual | — | 2026-08-12 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or OverweightNCT07369011Percent Change from Baseline in Body Weight | Phase 3 | Recruiting | Drug: Eloralintide, Placebo | Sleep Apnea, Obstructive, Obesity, Overweight | 800 | 2026-02-10 | Mar 2028 | ≤ 589 d | 2026-08-06 |
| AMGN | Amgen | $229.9B | Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure TherapyNCT07225686Change in Apnea-Hypopnea Index (AHI) from baseline at week 52 | Phase 3 | Recruiting | Drug: Maridebart cafraglutide, Placebo | Obesity, Obstructive Sleep Apnea | 250 | 2025-12-19 | 2027-09-29 | in 405 d | 2026-08-04 |
| NVO | Novo Nordisk A/S | — | AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep ApnoeaNCT07571109Relative change in body weight | Phase 3 | Recruiting | Drug: NNC0487-0111, Placebo (matched to NNC0487-0111) | Obesity, Overweight, Obstructive Sleep Apnoea | 300 | 2026-05-05 | 2028-06-26 | in 676 d | 2026-08-04 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or OverweightNCT05929079Percent Change from Baseline in Body Weight | Phase 3 | Completed | Drug: Retatrutide, Placebo | Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea | 1,152 | 2023-07-11 | 2026-06-16actual | — | 2026-07-30 |
| IXHL | Incannex Healthcare Ltd | $116M | RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSANCT06146101Change in apnea-hypopnea index (AHI) | Phase 2/3 | Completed | Drug: IHL-42X Low Dose, IHL-42X High Dose, Placebo, IHL-42X (Optimal Dose), Dronabinol, Acetazolamide, Placebo | Obstructive Sleep Apnea | 121 | 2024-05-02 | 2025-05-20actual | — | 2026-07-27 |
| LIVN | LivaNova | $4.4B | Treating Obstructive Sleep Apnea Using Targeted Hypoglossal NeurostimulationNCT04950894Rate of response to therapy when compared to no therapy for 6 months | Not applicable | Completed | Device: Hypoglossal Nerve Stimulation | Obstructive Sleep Apnea, OSA, Apnea, Apnea, Obstructive, Apnea, Obstructive Sleep, Apnea+Hypopnea, Hypopnea, Sleep | 107 | 2022-02-24 | 2024-10-17actual | — | 2026-07-17 |
| NVO | Novo Nordisk A/S | — | AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep ApnoeaNCT07571005Relative change in body weight | Phase 3 | Recruiting | Drug: NNC0487-0111, Placebo (matched to NNC0487-0111) | Obesity, Overweight, Obstructive Sleep Apnoea | 300 | 2026-05-05 | 2028-07-12 | in 692 d | 2026-07-13 |
| NYXH.BR | Nyxoah Inc. | $46M | Bi-lateral HGN Therapy in Real-World Patients -Post Approval Research InvestigationNCT07331285observationalChange in Apnea Hypopnea Index (AHI4%) | — | Recruiting | Device: This is a single arm study, all consented and eligible subjects will be implanted with the Genio® System 2.1 | Obstructive Sleep Apnea | 229 | Jun 2026 | Oct 2028 | ≤ 803 d | 2026-06-22 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or OverweightNCT05929066Percent Change From Baseline in Body Weight | Phase 3 | Completed | Drug: Retatrutide, Placebo | Obesity, Overweight, Osteoarthritis, Knee, Obstructive Sleep Apnea | 2,335 | 2023-07-10 | 2026-04-06actual | — | 2026-06-03 |
| INSP | Inspire Medical Systems, Inc. | $1.7B | Inspire Singapore StudyNCT06540716Inspiratory Overlap | Not applicable | Completed | Device: Inspire System | Obstructive Sleep Apnea, OSA, Sleep Apnea | 44 | 2024-07-25 | 2025-07-17actual | — | 2026-05-22 |
| RMD | ResMed | $31.7B | Data Collection Study to Review Novel Methods for Diagnosing Obstructive Sleep ApneaNCT06930404observationalCorrelation of measurement and obstructive sleep apnea status | — | Recruiting | Other: facial scans, videos and heart rate variability measurements | Obstructive Sleep Apnea (OSA) | 800 | 2025-09-15 | 2026-12-30 | in 132 d | 2026-05-19 |
| RMD | ResMed | $31.7B | INFORMing Patients With Oximetry Data to Improve MAD EngagementNCT07564310Mean overall patient reported experience measure (PREM) questionnaire score | Phase 4 | Not yet recruiting | Device: Narval MRD device, MyNarval intervention (Narval CC MAD + O2 ring + MyNarval smartphone application), | Obstructive Sleep Apnea (OSA) | 120 | 2026-06-01 | 2026-12-01 | in 103 d | 2026-05-04 |
| RMD | ResMed | $31.7B | Post Market Clinical Follow up of ResMed Mask SystemsNCT05262439Apnea Hypopnea Index (event/hour) | Not applicable | Recruiting | Device: New generation CPAP mask | Obstructive Sleep Apnea | 500 | 2022-05-26 | Jun 2027 | ≤ 314 d | 2026-04-29 |
| RMD | ResMed | $31.7B | Whitsundays (Nasal) Singapore External Clinical Study 1 ProtocolNCT05255744Subjective usability | Not applicable | Terminatedsponsor's stated reason: The study was discontinued prior to initiation because startup activities could not be completed within the planned timelines. | Device: Positive Airway Pressure (PAP) Therapy | Obstructive Sleep Apnea | 30 | 2025-03-28 | 2025-05-06actual | — | 2026-04-27 |
| RMD | ResMed | $31.7B | PAP Systems Internal Clinical Studies (ICS)NCT06173050Subjective outcomes parameters scores | Not applicable | Completed | Device: PAP System A (with Amalfi) then PAP System B (with CLA11), PAP System B (with CLA11) then PAP System A (with Amalfi) | Obstructive Sleep Apnea | 30 | 2024-06-20 | 2024-07-22actual | — | 2026-04-24 |
| RMD | ResMed | $31.7B | PAP Systems External Clinical Studies (ECS)NCT06562205(usability) Comparison of the usability of an investigational component/s of the PAP system to a comparison component/s of the PAP system and/or Criterion Score of 6 | Not applicable | Not yet recruiting | Device: PAP System A (with Amalfi) then PAP System B (with CLA11), PAP System B (with CLA11) then PAP System A (with Amalfi) | Obstructive Sleep Apnea | 30 | 2028-08-01 | 2028-10-01 | in 773 d | 2026-04-24 |
| NYXH.BR | Nyxoah S.A. | $46M | Dual-sided Hypoglossal neRvE stimulAtion for the treatMent of Obstructive Sleep Apnea (DREAM)NCT03868618Change in Apnea Hypopnea Index (AHI4%) | Not applicable | Active, not recruiting | Device: Genio™ system | Obstructive Sleep Apnea | 115 | 2020-10-14 | 2024-02-20actual | — | 2026-04-14 |
| INSP | Inspire Medical Systems, Inc. | $1.7B | Inspire UAS High Apnea Hypopnea Index (AHI)/High Body Mass Index (BMI) Post-Approval StudyNCT07113288observationalIncidence of Procedure and/or Device Related Adverse Events (Safety and Tolerability) | — | Recruiting | Device: Inspire® UAS System | Obstructive Sleep Apnea (OSA) | 70 | 2025-07-31 | 2032-01-01 | in 1,960 d | 2026-03-27 |
| NYXH.BR | Nyxoah S.A. | $46M | A Post-market Clinical Follow up of the Genio® System for the Treatment of Obstructive Sleep Apnea in AdultsNCT04031040Incidence of device-related Serious Adverse Events (SADEs) | Not applicable | Active, not recruiting | Device: Genio® system therapy | Obstructive Sleep Apnea | 110 | 2019-09-01 | 2026-10-30 | in 71 d | 2026-03-04 |
| RMD | ResMed | $31.7B | Evaluation of a Wearable PAP Device in a Tethered Configuration for the Treatment of Obstructive Sleep Apnoea.NCT07420140Subjective usability and overnight acceptability | Not applicable | Not yet recruiting | Device: Positive Airway Pressure | OSA - Obstructive Sleep Apnea | 15 | Mar 2026 | Jun 2026 | — | 2026-02-19 |
| RMD | ResMed | $31.7B | Study of Min-Max APAP Recommender ToolNCT07400861Mean residual AHI | Not applicable | Not yet recruiting | Device: CPAP with min-max recommender tool, CPAP with default settings | Obstructive Sleep Apnea (OSA) | 90 | 2026-04-01 | 2026-12-01 | in 103 d | 2026-02-12 |
| AXSM | Axsome Therapeutics, Inc. | $11.3B | Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled StudyNCT04789174results2026-01-26Change From Baseline in the Average of the DSST RBANS Scores at the End of Each Double-blind Treatment Period | Phase 4 | Completed | Drug: Solriamfetol, Placebo | Excessive Daytime Sleepiness, Obstructive Sleep Apnea, Impaired Cognitive Function | 59 | 2021-05-17 | 2022-09-19actual | — | 2026-01-26 |
| MLYS | Mineralys Therapeutics Inc. | $2.3B | A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and HypertensionNCT06785454Placebo-adjusted Change From Baseline in AHI at Week 4 | Phase 2 | Completed | Drug: Lorundrostat, Placebo | Obstructive Sleep Apnea, Hypertension | 48 | 2025-02-28 | 2025-12-17actual | — | 2026-01-13 |
| RMD | ResMed | $31.7B | Evaluation of a Novel Auto-Adjusting Positive Airway Pressure Algorithm for the Treatment of Obstructive Sleep Apnea Clinical StudyNCT06769607Comparison of the algorithm efficacy (AHI) to a clinically relevant data | Not applicable | Recruiting | Device: Investigational algorithm, Control algorithm | Obstructive Sleep Apnea | 80 | 2025-04-10 | Dec 2025 | — | 2025-12-02 |
| APMD | Apnimed | — | Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo)NCT05811247Change from Baseline in Apnea-Hypopnea Index (AHI) | Phase 3 | Completed | Drug: AD109, Placebo | OSA | 660 | 2023-08-28 | 2025-05-07actual | — | 2025-11-21 |
| APMD | Apnimed | — | Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)NCT05813275Change from Baseline in Apnea-Hypopnea Index (AHI) | Phase 3 | Completed | Drug: AD109, Placebo | OSA | 646 | 2023-09-16 | 2025-03-10actual | — | 2025-11-21 |
| LLY | Eli Lilly and Company | $1.15T | A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or OverweightNCT06649045Change from Baseline in Apnea-Hypopnea Index (AHI) | Phase 3 | Active, not recruiting | Drug: Orforglipron, Placebo | OSA, Overweight or Obesity | 600 | 2024-10-22 | Nov 2026 | ≤ 102 d | 2025-09-29 |
| INSP | Inspire Medical Systems, Inc. | $1.7B | Effects of Hypoglossal Nerve Stimulation on Cognition and Language in Down Syndrome and Obstructive Sleep ApneaNCT04801771Change in intelligence using the Kaufman Brief Intelligence Scale (KBIT-2) | Phase 3 | Active, not recruiting | Device: Inspire Upper Airway Stimulation (UAS) System | Down Syndrome, Obstructive Sleep Apnea | 57 | 2021-06-24 | 2027-02-28 | in 192 d | 2025-09-18 |
| INSP | Inspire Medical Systems, Inc. | $1.7B | EURO-STIM RegistryNCT06971796observationalApnea Hypopnea Index (AHI) | — | Recruiting | Device: Inspire UAS System | Obstructive Sleep Apnea, Obstructive Sleep Apnea (OSA) | 1,000 | 2025-05-26 | Apr 2035 | ≤ 3,175 d | 2025-09-08 |
| NYXH.BR | Nyxoah S.A. | $46M | Safety and Effectiveness of the Genio® bilAteral Stimulation for Treatment of Complete Concentric CollapsE and OSA.NCT05592002Primary Effectiveness Endpoint | Not applicable | Active, not recruiting | Device: Genio System | Sleep Apnea, Obstructive | 124 | 2022-12-28 | Sep 2026 | ≤ 41 d | 2025-09-05 |
| INSP | Inspire Medical Systems, Inc. | $1.7B | Adherence and Outcome of Upper Airway Stimulation (UAS) for OSA International RegistryNCT02907398observationalChange in Apnea Hypopnea (AHI) from Baseline to 12-Months | — | Unknown status | Device: Inspire therapy · Other: No intervention | Obstructive Sleep Apnea | 5,000 | 2016-10-19 | Sep 2025 | — | 2025-06-19 |
| NYXH.BR | Nyxoah S.A. | $46M | BilatEral Hypoglossal Nerve StimulaTion for TreatmEnt of ObstRuctive SLEEP Apnoea With and Without Complete Concentric CollapseNCT03763682Incidence of serious device-related adverse events recorded during the study | Not applicable | Terminatedsponsor's stated reason: The study was terminated due to operational challenges impacting protocol execution across sites. | Device: Genio(TM) bilateral hypoglossal nerve stimulation system | Obstructive Sleep Apnea | 42 | 2019-01-10 | 2021-06-28actual | — | 2025-06-06 |
| NYXH.BR | Nyxoah S.A. | $46M | An Extension Study to Assess the Long-term Safety of the Genio® SystemNCT05939141observationalLong-term safety | — | Not yet recruiting | Device: Genio System | Obstructive Sleep Apnea of Adult | 39 | Nov 2025 | 2029-07-17 | in 1,062 d | 2025-06-04 |
| APMD | Apnimed | — | Continuation Protocol for Obstructive Sleep Apnea (OSA)NCT06566820Number of Participants With Adverse Events (AES) and Serious Adverse Events (SAEs) | Phase 3 | Enrolling by invitation | Drug: Aroxybutynin and Atomoxetine | OSA | 1,280 | 2024-07-03 | 2026-06-30 | — | 2025-05-13 |
| LLY | Eli Lilly and Company | $1.15T | Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep ApneaNCT05412004results2025-04-30Change From Baseline in Apnea-Hypopnea Index (AHI) | Phase 3 | Completed | Drug: Tirzepatide, Placebo | Obstructive Sleep Apnea, Obesity | 469 | 2022-06-21 | 2024-03-12actual | — | 2025-04-30 |
| INSP | Inspire Medical Systems, Inc. | $1.7B | Pediatric Post-Approval RegistryNCT04457154observationalEvaluation of device and/or procedure related adverse events over time | — | Recruiting | Device: Inspire Upper Airway Stimulation System | Obstructive Sleep Apnea | 60 | 2021-11-30 | Dec 2027 | ≤ 498 d | 2025-02-25 |
| APMD | Apnimed | — | Study That Tests AD109 in Patients Taking GLP-1 DrugsNCT06400615Primary Objective (Adverse Events) | Phase 2 | Completed | Drug: AD109 | OSA | 40 | 2024-05-20 | 2024-12-26actual | — | 2025-02-19 |
| IXHL | Incannex Healthcare Ltd | $116M | Bioavailability, Bioequivalence and Tolerability of IHL-42X Compared to the Reference DrugsNCT05857384Bioavailability of IHL-42X | Phase 1 | Completed | Drug: IHL42X, Acetazolamide 250 MG, Dronabinol 2.5 MG | Obstructive Sleep Apnea | 125 | 2023-09-08 | 2024-07-31actual | — | 2025-01-17 |
| INSP | Inspire Medical Systems, Inc. | $1.7B | Inspire® Post-Approval Study / Protocol Number 2014-001NCT02413970Long-term Device-Related SAEs | Not applicable | Unknown status | Device: Inspire® UAS System | Obstructive Sleep Apnea | 127 | May 2015 | Mar 2025 | — | 2024-12-27 |
| INSP | Inspire Medical Systems, Inc. | $1.7B | The PREDICTOR Study: Assessing Diagnostic Predictors of Airway Collapse in Patients With Obstructive Sleep ApneaNCT05428839Measurement of pharyngeal width to determine if there is correlation between pharyngeal width and presence or absence of complete concentric collapse at the soft palate during drug induced sleep endoscopy | Not applicable | Unknown status | Diagnostic test: Pharyngeal width measurement | Sleep Apnea, Obstructive | 300 | 2022-05-11 | 2024-01-11actual | — | 2024-10-17 |
| RMD | ResMed | $31.7B | Registry on the Treatment of Central and Complex Sleep-Disordered Breathing With Adaptive Servo-VentilationNCT03032029observationalQuality of Life, assessed with the Functional Outcomes of Sleep Questionnaire (FOSQ) by comparing the score at baseline with the 12 months follow-up. | — | Completed | Device: Adaptive Servo-Ventilation | Central Sleep Apnea, Complex Sleep Apnea, Obstructive Sleep Apnea, Mixed Sleep Apnea | 847 | 2017-09-05 | 2022-06-30actual | — | 2024-10-16 |
| RMD | ResMed | $31.7B | Development of Advanced Leak Detection Technologies for Positive Airway Pressure Devices TherapiesNCT04741854Acoustic signals | Not applicable | Completed | Device: Positive Airway Pressure (PAP) Therapy | Obstructive Sleep Apnea (OSA) | 27 | 2020-08-26 | 2021-03-12actual | — | 2024-10-16 |
| OGN | Organon and Co | $3.6B | The Effects of Mometasone Furoate Nasal Spray in Subjects With Sleep-disordered Breathing (SDB) Associated With Perennial Allergic Rhinitis (Study P04726)NCT00359216results2009-08-03Apnea-Hypopnea Index | Phase 4 | Completed | Drug: Mometasone furoate nasal spray, Placebo | Perennial Allergic Rhinitis, Obstructive Sleep Apnea, Sleep Disorder | 30 | May 2006 | Jan 2008actual | — | 2024-05-23 |
| RMD | ResMed | $31.7B | Long-term Benefits of CPAP or MAD Treatment on the Sleep of OSAS PatientsNCT05435794observationalTo determine the evolution of deep slow-wave sleep at one year in OSA patients according to the treatment initiated by continuous positive pressure or mandibular advancement device (MAD). | — | Recruiting | Device: CPAP, MAD | OSA | 400 | 2022-07-15 | 2022-10-15actual | — | 2024-05-21 |
| AXSM | Axsome Therapeutics, Inc. | $11.3B | SUNOSI® (Solriamfetol) Pregnancy RegistryNCT06413420observationalLong-term Safety | — | Recruiting | Drug: Sunosi (solriamfetol), Other prescription wake-promoting medications or stimulants · Other: No treatment | Narcolepsy, Obstructive Sleep Apnea, Pregnant Women and Their Offspring | 1,731 | 2019-07-31 | Sep 2029 | ≤ 1,137 d | 2024-05-14 |
| RMD | ResMed | $31.7B | Whitsundays (Nasal) Mask Take Home Study (90 Days)NCT0603632911 point Likert Scale Questionnaire | Not applicable | Completed | Device: Group A : provided with 1 Whitsundays Nasal mask without a spare mask cushion, Group B : provided with 1 Whitsundays Nasal mask with 2 spare mask cushions | Obstructive Sleep Apnea | 120 | 2023-05-31 | 2023-11-06actual | — | 2024-02-29 |
| RMD | ResMed | $31.7B | Oran Park Mask External Clinical Study (3) Marketing Claims StudyNCT0607986611 point Likert Scale Questionnaire | Not applicable | Completed | Device: Mask A (Oran Park Mask) then Mask B (Evora Mask), Mask B (Evora Mask) then Mask A (Oran Park Mask) | Obstructive Sleep Apnea | 58 | 2023-10-04 | 2023-11-20actual | — | 2024-02-29 |
| RMD | ResMed | $31.7B | Personal Therapy Comfort Settings Pilot Clinical StudyNCT05376137Comparison of treatment continuance between the control group and active treatment group. | Not applicable | Completed | Device: continuous positive airway pressure (CPAP) | Obstructive Sleep Apnea | 66 | 2022-09-15 | 2023-06-30actual | — | 2023-11-18 |
| APMD | Apnimed | — | AD816 Crossover StudyNCT05793684Apnea-hypopnea index (AHI) 4%, AD816 vs. Placebo | Phase 2 | Completed | Drug: Period A, Period B, Period C | OSA, Obstructive Sleep Apnea | 25 | 2023-04-28 | 2023-11-09actual | — | 2023-11-15 |
| 4523.T | Eisai Inc. | $8.7B | A Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Participants With Moderate to Severe Obstructive Sleep Apnea, and in Adult and Elderly Participants With Moderate to Severe Chronic Obstructive Pulmonary DiseaseNCT04647383results2023-10-10OSA Cohort: Apnea-Hypopnea Index (AHI) on Day 8 of Treatment Periods 1 and 2 | Phase 1 | Completed | Drug: Placebo, Lemborexant 10 mg, Placebo, Lemborexant 10 mg | Sleep Apnea, Obstructive, Pulmonary Disease, Chronic Obstructive, Respiration Disorders | 63 | 2021-01-06 | 2022-02-10actual | — | 2023-10-10 |
| APMD | Apnimed | — | Crossover Trial of AD036 in Obstructive Sleep ApneaNCT04445688results2023-08-21Apnea-Hypopnea Index | Phase 2 | Completed | Drug: AD036, Atomoxetine, Placebo | Obstructive Sleep Apnea | 62 | 2020-07-15 | 2020-12-01actual | — | 2023-09-14 |
| APMD | Apnimed | — | Trial of AD113 and Atomoxetine in OSA Patients With HypertensionNCT04905979Change in hypoxic burden (HB, total area under the respiratory event-related desaturation curve) | Phase 2 | Completed | Drug: AD113, Atomoxetine | Obstructive Sleep Apnea, Hypertension | 21 | 2021-07-31 | 2023-01-31actual | — | 2023-08-21 |
| ISRG | Intuitive Surgical | $138.2B | Treatment of Obstructive Sleep Apnea (OSA) With the da Vinci® SP™ Surgical SystemNCT04795817observationalType 1 Polysomnography (PSG) | — | Completed | Device: Transoral Robotic Surgery | Obstructive Sleep Apnea | 25 | 2021-01-27 | 2023-01-25actual | — | 2023-05-31 |
| AXSM | Axsome Therapeutics, Inc. | $11.3B | Evaluate Sunosi® PK in Breast Milk and Plasma of Healthy Postpartum Women Following Single Dose Oral AdministrationNCT05008341Maximum Concentration (Cmax) of Solriamfetol in Breast Milk and Plasma | Phase 1 | Completed | Drug: Solriamfetol 150 mg Oral Tablet | Narcolepsy, Obstructive Sleep Apnea, Excessive Daytime Somnolence, Excessive Sleepiness, Postpartum | 6 | 2021-08-27 | 2022-04-15actual | — | 2023-04-14 |
| APMD | Apnimed | — | Study for Efficacy and Dose Escalation of AD313 + Atomoxetine (SEED)NCT05101122results2023-04-07Apnea-Hypopnea Index (AHI)4% Events Per Hour | Phase 1/2 | Completed | Drug: Dosing 1: Atomoxetine, AD313 | Obstructive Sleep Apnea | 15 | 2021-10-19 | 2022-04-18actual | — | 2023-04-07 |
| APMD | Apnimed | — | Crossover Trial of AD109 in Obstructive Sleep ApneaNCT04580394results2023-01-31Change in Hypoxic Burden (HB) Log10HB[(%*Min)/Hour] | Phase 2 | Completed | Drug: AD109, Atomoxetine, R-oxybutynin, Placebo · Diagnostic test: Digit System Substitution Test | Obstructive Sleep Apnea | 60 | 2020-10-27 | 2021-05-28actual | — | 2023-01-31 |
| APMD | Apnimed | — | Trial of AD036 in Obstructive Sleep ApneaNCT03845023results2023-01-17Apnea Hypopnea Index (AHI) | Phase 2 | Completed | Drug: AD036 Dose 1, AD036 Dose 2, AD036 Dose 3, Placebo | Obstructive Sleep Apnea | 140 | 2019-03-07 | 2019-10-23actual | — | 2023-01-17 |
| APMD | Apnimed | — | AD109 Dose Finding in Mild to Moderate OSANCT04631107results2022-12-22Change in Hypoxic Burden (HB) Log Transformed - Log10HB[(%*Min)/h] | Phase 2 | Completed | Drug: AD109 dose1- A, AD109 dose2- B, Placebo- C | Obstructive Sleep Apnea | 32 | 2020-12-22 | 2021-05-31actual | — | 2022-12-22 |
| APMD | Apnimed | — | Crossover Trial of AD182 and AD504 in Obstructive Sleep ApneaNCT04645524Apnea-Hypopnea Index (AHI, average number of events for every hour of sleep) | Phase 2 | Completed | Drug: AD182, AD504, Placebo · Diagnostic test: Polysomnography | Obstructive Sleep Apnea | 15 | 2020-12-01 | 2021-09-01actual | — | 2022-09-02 |
| INSP | Inspire Medical Systems, Inc. | $1.7B | Inspire Home Study: Utilization of Home Monitoring During Therapy Optimization in Patients With an Inspire Upper Airway Stimulation System (Comparison of Home Sleep Testing vs. In-lab Polysomnography Testing)NCT04416542Comparison of Apnea-Hypopnea Index (AHI), between the two randomization arms | Not applicable | Completed | Diagnostic test: Home Sleep Testing | Obstructive Sleep Apnea | 64 | 2020-07-28 | 2022-06-10actual | — | 2022-06-21 |
| RMD | ResMed | $31.7B | Validation of ApneaLink Air Home Sleep Testing in the Diagnosis of Obstructive Sleep Apnea in Adolescent ChildrenNCT03748771results2021-11-15Accuracy of HST Compared to ALT (ApneaLink Lab Testing) and PSG (Polysomnography) | — | Completed | Device: ApneaLink Air | Sleep Apnea, Obstructive | 20 | 2018-12-01 | 2020-02-28actual | — | 2021-11-15 |
| NYXH.BR | Nyxoah S.A. | $46M | BiLAteral Hypoglossal Nerve Stimulation for Treatment of Obstructive Sleep Apnoea (BLAST OSA)NCT03048604Safety (Incidence of serious device-related adverse events) | Not applicable | Completed | Device: Genio(TM) bilateral hypoglossal nerve stimulation system | Obstructive Sleep Apnea of Adult | 27 | 2017-03-30 | 2018-09-10actual | — | 2021-10-11 |
| RMD | ResMed | $31.7B | Evaluating the Efficacy of PAP Therapy for Treating OSA in the Home EnvironmentNCT04744038Usability | Not applicable | Completed | Device: Positive Airway Pressure (PAP) Therapy | Obstructive Sleep Apnea (OSA) | 108 | 2020-08-12 | 2021-03-05actual | — | 2021-07-13 |
| RMD | ResMed | $31.7B | Evaluation of an Incentive-based Intervention to Improve 90-day Adherence in PAP-Naive PatientsNCT03851094results2021-06-15Mean PAP Usage at 90 Days | Not applicable | Completed | Behavioral: Wellth app | Obstructive Sleep Apnea | 166 | 2019-03-11 | 2020-05-18actual | — | 2021-06-15 |
| RMD | ResMed | $31.7B | Evaluation of a Health Dashboard Intervention to Improve Engagement With CPAP Therapy in PAP-Naïve Patients: Project NeoNCT04912635Mean CPAP use hours | Not applicable | Completed | Other: Neo App | Sleep Apnea, Obstructive | 300 | 2020-09-25 | 2020-12-19actual | — | 2021-06-03 |
| RMD | ResMed | $31.7B | Foam Mask - Assessment of Bioburden in a New Mask Seal MaterialNCT00773721Measurement of bacterial accumulation in the new material. | Not applicable | Completed | Device: CPAP mask | Obstructive Sleep Apnea (OSA) | 20 | Oct 2008 | Dec 2008actual | — | 2021-02-04 |
| RMD | ResMed | $31.7B | Improved Automatic CPAP Algorithm to Treat Obstructive Sleep Apnea (OSA)NCT00850434Physiological sleep signals including EEG, Sp02, respiratory effort and nasal flow, will be recorded, analysed and reported in the form of a series of indices, which are the outcome variables of the study. | Not applicable | Completed | Device: Modified AutoSet Algorithm, Standard AutoSet Algorithm | Obstructive Sleep Apnea (OSA) | 20 | Nov 2005 | Sep 2008actual | — | 2021-02-04 |
| RMD | ResMed | $31.7B | Performance of the Tasman Continuous Positive Airway Pressure (CPAP) SystemNCT01171066To determine if the efficacy of the treatment is clinically equivalent to or better than the predicate device (S8 Escape) | Not applicable | Completed | Device: Tasman CPAP system | Obstructive Sleep Apnea | 57 | Jun 2010 | Oct 2012actual | — | 2021-02-04 |
| RMD | ResMed | $31.7B | Analysis of a New Mask for Positive Airway Pressure (PAP) Device UsersNCT01847846To measure and compare the prevalence of microorganisms within the new mask over a period of 8 weeks | Not applicable | Completed | Device: CPAP mask - prototype | Obstructive Sleep Apnea | 23 | Jul 2014 | Oct 2014actual | — | 2021-02-04 |
| RMD | ResMed | $31.7B | Usability Evaluation of Menai CPAP MasksNCT02364375Usability Performance Evaluation | Not applicable | Completed | Device: Menai mask (full face), Menai Standard mask (full face), Menai mask (nasal), Menai Standard mask (nasal), Menai mask (pillows), Menai Standard mask (pillows) | Obstructive Sleep Apnea | 30 | May 2015 | Jul 2015actual | — | 2021-02-04 |
| RMD | ResMed | $31.7B | Comparison of Two Continuous Positive Airway Pressure SystemsNCT02535234Subjective usability ratings of the prototype system using a visual analogue scale, compared to a reference level and the second full system. | Not applicable | Completed | Device: Novel System, Traditional System | Obstructive Sleep Apnoea | 30 | Apr 2016 | Jun 2016actual | — | 2021-02-04 |
| RMD | ResMed | $31.7B | Vent Flow Study of Prototype Nasal CPAP MaskNCT02805777Changes in vent flow of the mask system, which will be recorded on a flow testing rig (units= LPM). Baseline flow in LPM will be compared to that at the conclusion of the trial. | Not applicable | Withdrawnsponsor's stated reason: Study not required due to change in device | Device: CPAP mask | Obstructive Sleep Apnea (OSA) | 0 | 2017-05-01 | Dec 2017 | — | 2021-02-04 |
| RMD | ResMed | $31.7B | Nebula Study - Screener Apps and HSAT vs. PSG ComparisonNCT04597749AHI value. Clinical decision for treatment output (Y to CPAP or N to CPAP) of Screener apps and HSAT compared to PSG. | Not applicable | Completed | Diagnostic test: PSG, Home Sleep Apnea Test with FDA cleared devices · Other: Non-Contact Screening App | Sleep Apnea, Obstructive | 50 | 2020-10-27 | 2020-12-31actual | — | 2021-02-04 |
| RMD | ResMed | $31.7B | Bioburden and Usability Evaluation of a Nasal Prototype CPAP MaskNCT02255539Changes from baseline in Bioburden and Impedance of the prototype mask components at 6 weeks | Not applicable | Completed | Device: Geelong Prototype Mask | Obstructive Sleep Apnea | 42 | Jan 2015 | Mar 2015actual | — | 2021-02-01 |
| RMD | ResMed | $31.7B | Assessment of the Effect of PAP on Energy and Vitality in Mild OSA Patients: The Merge StudyNCT02699463results2021-01-26Change in Quality of Life Using the Energy and Vitality Subscale of the Short Form 36 (SF-36) Questionnaire | Not applicable | Completed | Device: Continous Positive Airway Pressure · Other: Control Group | Obstructive Sleep Apnea | 301 | Dec 2016 | May 2019actual | — | 2021-01-26 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in OSANCT02806895results2020-06-16Standard Deviation of Lateral Position (SDLP) at 2 Hours Post-dose (Approximately at Tmax) | Phase 2 | Completed | Drug: JZP-110, Placebo | Obstructive Sleep Apnea, Excessive Sleepiness | 34 | 2016-07-05 | 2019-05-28actual | — | 2021-01-14 |
| RMD | ResMed | $31.7B | An Exploratory Investigation of the Use of Drive App to Measure Sleep Parameters in Users of CPAP TherapyNCT04500327Identify any failures when using the Drive app for users of CPAP therapy | Not applicable | Unknown status | Other: Drive app · Device: Non contact motion sensor | Obstructive Sleep Apnea | 12 | 2020-06-25 | Jun 2021 | — | 2020-08-05 |
| INSP | Inspire Medical Systems, Inc. | $1.7B | Inspire® Upper Airway Stimulation (UAS) System German Post-Market StudyNCT02293746Number of Reported SAEs / Procedure & Device Related AEs | Phase 4 | Completed | Device: Inspire® Upper Airway Stimulation (UAS) System | Obstructive Sleep Apnea | 60 | Jun 2014 | 2016-12-11actual | — | 2020-07-02 |
| RMD | ResMed | $31.7B | Evaluation of ApneaLink Plus Scoring CapabilitiesNCT00823134results2020-05-12Assessment of the Apnoea-Hypopnea-Index (Number of Apneas (All Apneas, Obstructive, Mixed, Central) and Number of Hypopneas) Between ApneaLink Plus and a PSG System Within the Same Evaluation Period | Not applicable | Completed | Device: ApneaLink Plus | Sleep Apnea, Central, Sleep Apnea, Obstructive | 23 | Dec 2008 | Mar 2009actual | — | 2020-05-12 |
| RMD | ResMed | $31.7B | Comparison of Auto-Adjusting Positive Airway Pressure DevicesNCT02357706results2020-04-20Mean Apnoea-Hypopnoea-Index (AHI) | Not applicable | Completed | Device: APAP A (ResMed AirSense AutoSet), APAP B (Apex iCH Auto) | Obstructive Sleep Apnea | 20 | Jan 2015 | Jun 2015actual | — | 2020-04-20 |
| RMD | ResMed | $31.7B | Narval CC Mandibular Repositioning Device in the Second-line Treatment of Severe Obstructive Sleep Apnea Hypopnea (OSAH)NCT01326143observationalPercentage of patients with Apnea/Hypopnea Index (AHI) reduced by at least 50% compared to baseline measured by Polygraphy/Polysomnography (PG/PSG) | — | Completed | Device: ORM Narval MRD | Obstructive Sleep Apnea Syndrome | 360 | May 2011 | Feb 2019actual | — | 2020-04-02 |
| RMD | ResMed | $31.7B | Prospective Cohort Study of Patients Intolerant to High Pressure Under Continuous Positive Airway Pressure Treated With Bilevel Positive Airway Pressure as Second-line Therapy.NCT02930460observationalCompliance | — | Terminated | — | Obstructive Sleep Apnea | 30 | Nov 2016 | Nov 2018actual | — | 2020-02-28 |
| 4523.T | Eisai Inc. | $8.7B | Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Healthy Subjects and Adult and Elderly Subjects With Mild Obstructive Sleep ApneaNCT03471871results2020-01-18HV Cohort: Peripheral Oxygen Saturation (SpO2) During Total Sleep Time (TST) on Day 1 of Treatment | Phase 1 | Completed | Drug: Placebo, Lemborexant 10 mg, Lemborexant 25 mg, Placebo, Lemborexant 10 mg | Obstructive Sleep Apnea, Healthy Subjects | 146 | 2018-02-21 | 2018-08-03actual | — | 2020-02-17 |
| RMD | ResMed | $31.7B | AutoSet for Her Quality of Life Clinical TrialNCT02400073results2019-10-02Assessment of Quality of Life Using the Functional Outcomes of Sleep Questionnaire (FOSQ) | Not applicable | Completed | Device: AutoSet for Her | Obstructive Sleep Apnea | 122 | 2015-03-19 | 2017-01-05actual | — | 2019-10-02 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | "Six-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA"NCT02348619results2019-09-09Change in the Maintenance of Wakefulness Test (MWT) | Phase 3 | Completed | Drug: JZP-110 | Obstructive Sleep Apnea | 174 | May 2015 | Nov 2016actual | — | 2019-09-09 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | "Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA"NCT02348606results2019-07-23Change in Maintenance of Wakefulness Test (MWT) From Baseline to Week 12 | Phase 3 | Completed | Drug: JZP-110, Placebo oral tablet | Obstructive Sleep Apnea | 476 | May 2015 | Dec 2016actual | — | 2019-07-23 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | "A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA"NCT02348632results2019-06-25Change in Epworth Sleepiness Scale (ESS) Score | Phase 3 | Completed | Drug: JZP-110 | Narcolepsy, Obstructive Sleep Apnea | 645 | May 2015 | Dec 2017actual | — | 2019-06-25 |
| NVO | Novo Nordisk A/S | — | Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep ApnoeaNCT01557166results2015-02-09Change From Baseline in Apnoea-hypopnoea Index (AHI) | Phase 3 | Completed | Drug: liraglutide, placebo | Metabolism and Nutrition Disorder, Obesity, Obstructive Sleep Apnoea | 359 | 2012-06-07 | 2013-06-01actual | — | 2017-11-01 |
| LIVN | LivaNova | $4.4B | PErsonalized and Adaptive Kinesthetic stImulation Therapy, Based on Cardio-respiratory Holter moNitoring, for Sleep Apnea syndrOmesNCT02789748Rate of responder to the therapy | Not applicable | Completed | Device: Kinesthetic stimulation | Obstructive Sleep Apnea Syndrome | 42 | 2016-06-01 | 2017-10-02actual | — | 2017-10-05 |
| LIVN | LivaNova | $4.4B | HYpopnea and Apnea Detection and Treatment Performance of a New cardiOreSpiratory Holter MonitorNCT03300037observationalPerformance of real-time detector of apnea and hypopnea: sensitivity and positive predictive value of the detector will be calculated when comparing automatically detected respiratory events to gold-standard PSG scoring of apnea/hypopnea events. | — | Completed | Device: Kinesthetic stimulation | Sleep Apnea, Obstructive | 46 | 2014-09-01 | 2015-04-16actual | — | 2017-10-03 |
| RMD | ResMed | $31.7B | Clinical Impact of 2 Types of Mandibular Retention Devices - Narval O.R.M CadCam Design vs Narval O.R.M Traditional Design - on Obstructive Sleep Apnea (OSA) Therapy: ESTAMPS StudyNCT02755662upper airway volume | Not applicable | Completed | Device: Mandibular Retention Device | Obstructive Sleep Apnea Syndrome | 12 | May 2016 | Jul 2017actual | — | 2017-09-28 |
| INSP | Inspire Medical Systems, Inc. | $1.7B | Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)NCT01161420results2014-12-15Apnea Hypopnea Index | Phase 3 | Completed | Device: Inspire Upper Airway Stimulation System | Obstructive Sleep Apnea | 929 | Jul 2010 | Mar 2013actual | — | 2017-08-25 |
| RMD | ResMed | $31.7B | Validation of the ApneaLink Sleep Screener for Obstructive Sleep Apnea (OSA)NCT00354614results2017-06-28observationalSensitivity and Specificity | — | Completed | Device: ApneaLink Sleep Screener | Obstructive Sleep Apnea | 81 | Jun 2006 | Mar 2007actual | — | 2017-06-28 |
| RMD | ResMed | $31.7B | Study of the Usability and Efficacy of a New Pediatric CPAP MaskNCT01312948results2012-03-19Usability Ratings of the Pixi Paediatric Mask Compared With the Child's Current Mask | Not applicable | Completed | Device: Prototype mask (known as Pixi) | Obstructive Sleep Apnea, Respiratory Insufficiency | 6 | Jan 2011 | Jun 2011actual | — | 2017-06-26 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Obstructive Sleep Apnea is matched — 8 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Obstructive Sleep Apnea
- Obstructive Sleep Apnea (OSA)
- OSA
- Sleep Apnea, Obstructive
- Obstructive Sleep Apnea Syndrome
- Obstructive Sleep Apnoea
- OSA - Obstructive Sleep Apnea
- Obstructive Sleep Apnea of Adult
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Obstructive Sleep Apnea” (a text search, wider than this page)